<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673670</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-CO-204</org_study_id>
    <nct_id>NCT03673670</nct_id>
  </id_info>
  <brief_title>Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD</brief_title>
  <official_title>A Phase II, Randomized, Double Blind, Placebo Controlled, Three-way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered in Addition to Open Label Tiotropium/Olodaterol in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of 3 days of twice daily treatment of two different doses
      of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition
      to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic
      obstructive pulmonary disease (COPD). Patients will receive each of the three treatment
      combinations in a randomized sequence using a crossover design
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RPL554 is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) which
      are known to have a role in modulating the inflammatory airway response in respiratory
      diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have
      anti-inflammatory properties and there is also evidence to suggest that combined inhibition
      of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator. The
      two doses of RPL554 (1.5 mg and 6 mg)have been selected based on the results from prior
      studies investigating single and multiple ascending doses in healthy subjects, single doses
      in asthmatics, single/multiple ascending doses in COPD patients, and 3 days of dosing in COPD
      patients. These doses were demonstrated to be both effective as a bronchodilator and well
      tolerated.

      The purpose of the study is to investigate if RPL554 has an additive bronchodilator effect
      when administered in combination with a commonly used anticholinergic/Î²-agonist combination
      medication, tiotropium/olodaterol (Respimat), in this patient population measured by the peak
      forced expiratory volume in one second (FEV1), and forced vital capacity (FVC).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Actual">November 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The nebulizer cup will be obscured so the contents are not visible to the subject and the blinded study staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Peak FEV1 on Day 3</measure>
    <time_frame>Change from pre-dose at 5, 15 and 30 minutes and 1, 1.5, 2 &amp; 4 hours on Day 3</time_frame>
    <description>Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Trough FEV1 on Day 4</measure>
    <time_frame>Change from pre-dose on Day 1 to pre-dose on Day 4</time_frame>
    <description>Change from baseline to morning trough FEV1 on Day 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC0-4h FEV1 on Day 3</measure>
    <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the morning dose)</time_frame>
    <description>Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC0-12h FEV1 on Day 3</measure>
    <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 3 (after the morning dose)</time_frame>
    <description>Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FEV1 on Day 1</measure>
    <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 1 (after the morning dose), with the maximum change reported</time_frame>
    <description>Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FEV1 After Evening Dose on Day 3</measure>
    <time_frame>Change from pre-dose to each of the ollowing timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the evening dose), with the maximum change reported</time_frame>
    <description>Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC0-12h FEV1 on Day 1</measure>
    <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 1 (after the morning dose)</time_frame>
    <description>Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Onset of Action on Day 1</measure>
    <time_frame>Change from pre-dose to the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2 hours on Day 1 (after the morning dose)</time_frame>
    <description>Time to &gt;10% increase in FEV1 from pre-first dose, censored at 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume on Day 1</measure>
    <time_frame>Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)</time_frame>
    <description>Change in residual volume during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Volume on Day 3</measure>
    <time_frame>Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)</time_frame>
    <description>Change in residual volume during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Residual Capacity on Day 1</measure>
    <time_frame>Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)</time_frame>
    <description>Change in functional residual capacity during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Residual Capacity on Day 3</measure>
    <time_frame>Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)</time_frame>
    <description>Change in functional residual capacity during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Airway Conductance on Day 1</measure>
    <time_frame>Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)</time_frame>
    <description>Change in specific airway conductance during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Airway Conductance on Day 3</measure>
    <time_frame>Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)</time_frame>
    <description>Change in specific airway conductance during treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>1.5 mg RPL554 and tiotropium/olodaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg RPL554 and tiotropium/olodaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and tiotropium/olodaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554 Suspension</intervention_name>
    <description>A PDE3/4 inhibitor</description>
    <arm_group_label>1.5 mg RPL554 and tiotropium/olodaterol</arm_group_label>
    <arm_group_label>6 mg RPL554 and tiotropium/olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo solution</description>
    <arm_group_label>Placebo and tiotropium/olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/olodaterol (Respimat)</intervention_name>
    <description>An anticholinergic/Î²-agonist combination medication</description>
    <arm_group_label>1.5 mg RPL554 and tiotropium/olodaterol</arm_group_label>
    <arm_group_label>6 mg RPL554 and tiotropium/olodaterol</arm_group_label>
    <arm_group_label>Placebo and tiotropium/olodaterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Male or female aged 40 and 80 years

          3. For males, not to donate sperm and either be sexually abstinent or use contraception
             as specified by the protocol. For females, be of non-childbearing potential or use a
             highly effective form of contraception

          4. 12-lead ECG with heart rate between 45 and 90 beats per minute, QTcF â¤450 msec for
             males, and â¤ 470 msec for females, QRS interval â¤120 msec and no clinically
             significant abnormality including morphology

          5. Screening Holter report with a minimum of 18 hours recording that is able to be
             evaluated for rhythm analysis showing no abnormality which indicates a significant
             impairment of patient safety or which may significantly impair interpretation

          6. Capable of complying with all study restrictions and procedures including ability to
             use the study nebulizer and RespimatÂ® correctly.

          7. Body mass index (BMI) between 18 and 36 kg/m2 and minimum weight of 45 kg.

          8. COPD diagnosis for at least 1 year and clinically stable COPD for 4 week

          9. Post-bronchodilator (two puffs of salbutamol/albuterol followed by two puffs of
             ipratropium) spirometry at Screening:

               -  Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of â¤0.70

               -  Post-bronchodilator FEV1 â¥30 % and â¤70% of predicted normal

               -  Demonstrates â¥150 mL increase from pre-bronchodilator FEV1

         10. A chest X-ray showing no abnormalities, which are both clinically significant and
             unrelated to COPD.

        12. Meet the concomitant medication restrictions and be expected to do so for the rest of
        the study.

        13. Current and former smokers with smoking history of â¥10 pack years. 14. Capable of
        withdrawing from long acting bronchodilators for the duration of the study, and short
        acting bronchodilators for 8 hours prior to dosing.

        Exclusion Criteria:

          1. A history of life-threatening COPD including Intensive Care Unit admission and/or
             requiring intubation.

          2. COPD exacerbation requiring oral or parenteral steroids, or lower respiratory tract
             infection requiring antibiotics, in the last 3 months

          3. A history of one or more hospitalizations for COPD in the last 12 months

          4. Intolerance or hypersensitivity to tiotropium, olodaterol, atropine, ipratropium, or
             RPL554.

          5. Evidence of cor pulmonale or clinically significant pulmonary hypertension.

          6. Other respiratory disorders

          7. Previous lung resection or lung reduction surgery.

          8. Use of oral COPD medications, except mucolytics, in the last 3 months

          9. Pulmonary rehabilitation, unless such treatment has been stable in the last 4 weeks

         10. History of, or reason to believe a patient has, drug or alcohol abuse within the past
             5 years.

         11. Inability to perform acceptable spirometry or whole body plethysmography

         12. Received an experimental drug within 30 days or five half lives, whichever is longer.

         13. Patients with uncontrolled disease that the Investigator believes are clinically
             significant. This includes any hepatic disease, or an alanine aminotransferase or
             aspartate aminotransferase&gt;2 x upper limit of normal (ULN).

         14. Documented cardiovascular disease: arrhythmias, angina, recent (&lt;1 year) or suspected
             myocardial infarction, congestive heart failure, unstable or uncontrolled
             hypertension, or diagnosis of hypertension in the last 3 months

         15. Use of non-selective oral Î²-blockers.

         16. Major surgery (requiring general anesthesia) in the last 6 weeks or will not have
             fully recovered from surgery, or planned surgery through the end of the study.

         17. A disclosed history or one known to the Investigator, of significant non compliance in
             previous investigational studies or with prescribed medications.

         18. Required use of oxygen therapy, even on an occasional basis.

         19. Symptomatic prostatic hyperplasia or bladder-neck obstruction or with narrow-angle
             glaucoma.

         20. History of malignancy of any organ system within 5 years, with the exception of
             localized skin cancers (basal or squamous cell).

         21. Clinically significant abnormal values for safety laboratory tests (hematology,
             biochemistry, virology or urinalysis) as determined by the Investigator

         22. Any other reason that the Investigator considers makes the patient unsuitable to
             participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site Partners, LLC</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Biomedical Research Holdings, d/b/a Vitalink Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Clinical Trials LTD,</name>
      <address>
        <city>London</city>
        <zip>W1G8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <results_first_submitted>June 20, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2019</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Bronchodilation</keyword>
  <keyword>FEV1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03673670/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03673670/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose RPL554 Then High Dose RPL554 Then Placebo</title>
          <description>1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="P2">
          <title>Low Dose RPL554 Then Placebo Then High Dose RPL554</title>
          <description>1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="P3">
          <title>High Dose RPL554 Then Low Dose RPL554 Then Placebo</title>
          <description>6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="P4">
          <title>High Dose RPL554 Then Placebo Then Low Dose RPL554</title>
          <description>6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="P5">
          <title>Placebo Then Low Dose RPL554 Then High Dose RPL554</title>
          <description>Placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="P6">
          <title>Placebo Then High Dose RPL554 Then Low Dose RPL554</title>
          <description>Placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alpha 1 antitrypsin deficiency</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 1 (7-14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 2 (7-14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pre-dose FEV1 not 20% baseline</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose RPL554 Then High Dose RPL554 Then Placebo</title>
          <description>1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="B2">
          <title>Low Dose RPL554 Then Placebo Then High Dose RPL554</title>
          <description>1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="B3">
          <title>High Dose RPL554 Then Low Dose RPL554 Then Placebo</title>
          <description>6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="B4">
          <title>High Dose RPL554 Then Placebo Then Low Dose RPL554</title>
          <description>6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="B5">
          <title>Placebo Then Low Dose RPL554 Then High Dose RPL554</title>
          <description>Placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="B6">
          <title>Placebo Then High Dose RPL554 Then Low Dose RPL554</title>
          <description>Placebo twice daily plus tiotropium 5/5 mcg once daily for 3 days then 6 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days then 1.5 mg RPL554 twice daily plus tiotropium 5/5 mcg once daily for 3 days with a 7-14 day washout between treatment periods</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="13"/>
            <count group_id="B7" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" lower_limit="43" upper_limit="75"/>
                    <measurement group_id="B2" value="64.5" lower_limit="53" upper_limit="74"/>
                    <measurement group_id="B3" value="63.0" lower_limit="45" upper_limit="74"/>
                    <measurement group_id="B4" value="63.0" lower_limit="43" upper_limit="77"/>
                    <measurement group_id="B5" value="67.0" lower_limit="49" upper_limit="76"/>
                    <measurement group_id="B6" value="61.0" lower_limit="48" upper_limit="73"/>
                    <measurement group_id="B7" value="64.0" lower_limit="43" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Peak FEV1 on Day 3</title>
        <description>Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3</description>
        <time_frame>Change from pre-dose at 5, 15 and 30 minutes and 1, 1.5, 2 &amp; 4 hours on Day 3</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 on Day 3</title>
          <description>Change from baseline FEV1 to peak FEV1 (measured as the greatest value in the 4 hours post-dose after the morning dose) on Day 3</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.565" spread="0.2783"/>
                    <measurement group_id="O2" value="0.506" spread="0.2506"/>
                    <measurement group_id="O3" value="0.519" spread="0.2809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.168</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.991</ci_lower_limit>
            <ci_upper_limit>1.052</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.731</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>0.995</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.966</ci_lower_limit>
            <ci_upper_limit>1.025</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Trough FEV1 on Day 4</title>
        <description>Change from baseline to morning trough FEV1 on Day 4</description>
        <time_frame>Change from pre-dose on Day 1 to pre-dose on Day 4</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Trough FEV1 on Day 4</title>
          <description>Change from baseline to morning trough FEV1 on Day 4</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.2496"/>
                    <measurement group_id="O2" value="0.178" spread="0.2123"/>
                    <measurement group_id="O3" value="0.150" spread="0.2218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.115</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.994</ci_lower_limit>
            <ci_upper_limit>1.055</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.111</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.994</ci_lower_limit>
            <ci_upper_limit>1.055</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC0-4h FEV1 on Day 3</title>
        <description>Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
        <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC0-4h FEV1 on Day 3</title>
          <description>Change from baseline FEV1 to AUC FEV1 over 4 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters. (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.429" spread="0.2518"/>
                    <measurement group_id="O2" value="0.390" spread="0.2246"/>
                    <measurement group_id="O3" value="0.377" spread="0.2485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.303</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.987</ci_lower_limit>
            <ci_upper_limit>1.043</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC0-12h FEV1 on Day 3</title>
        <description>Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
        <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 3 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC0-12h FEV1 on Day 3</title>
          <description>Change from baseline in AUC over 12 hours post-dose after the morning dose on Day 3. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.390" spread="0.2426"/>
                    <measurement group_id="O2" value="0.347" spread="0.2219"/>
                    <measurement group_id="O3" value="0.337" spread="0.2447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.067</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.998</ci_lower_limit>
            <ci_upper_limit>1.057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.395</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.984</ci_lower_limit>
            <ci_upper_limit>1.042</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FEV1 on Day 1</title>
        <description>Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1</description>
        <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 1 (after the morning dose), with the maximum change reported</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 on Day 1</title>
          <description>Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the morning dose on Day 1</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.490" spread="0.2219"/>
                    <measurement group_id="O2" value="0.467" spread="0.2393"/>
                    <measurement group_id="O3" value="0.445" spread="0.2306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.404</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.984</ci_lower_limit>
            <ci_upper_limit>1.039</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FEV1 After Evening Dose on Day 3</title>
        <description>Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3</description>
        <time_frame>Change from pre-dose to each of the ollowing timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4 hours on Day 3 (after the evening dose), with the maximum change reported</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 After Evening Dose on Day 3</title>
          <description>Change from baseline FEV1 to peak FEV1 in the 4 hours post-dose after the evening dose on Day 3</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.453" spread="0.2625"/>
                    <measurement group_id="O2" value="0.405" spread="0.2581"/>
                    <measurement group_id="O3" value="0.324" spread="0.2211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.023</ci_lower_limit>
            <ci_upper_limit>1.101</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC0-12h FEV1 on Day 1</title>
        <description>Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
        <time_frame>Change from pre-dose to each of the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12 hours on Day 1 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC0-12h FEV1 on Day 1</title>
          <description>Change from baseline FEV1 to AUC FEV1 over 12 hours post-dose after the morning dose on Day 1. The endpoint is measured as AUC/interval length (average) and measured in liters (Note: Endpoint is AUC/interval length (average) so the units are in liters.)</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.333" spread="0.1815"/>
                    <measurement group_id="O2" value="0.308" spread="0.1854"/>
                    <measurement group_id="O3" value="0.303" spread="0.1920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.096</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>1.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hierarchical fixed-sequence testing strategy was employed to test the significance of the treatment effect for each of the two RPL554 doses against placebo, starting with the highest dose (6 mg). If a statistically significant difference was found at the 2-sided Î± level of 5%, the testing proceeded with the next highest dose. Otherwise, testing was stopped, and the remaining null hypotheses were accepted without testing.</non_inferiority_desc>
            <p_value>0.862</p_value>
            <method>ANCOVA</method>
            <param_type>GeoMean Ratio</param_type>
            <param_value>1.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.979</ci_lower_limit>
            <ci_upper_limit>1.025</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Onset of Action on Day 1</title>
        <description>Time to &gt;10% increase in FEV1 from pre-first dose, censored at 2 hours</description>
        <time_frame>Change from pre-dose to the following timepoints: 5, 15 and 30 minutes and 1, 1.5, 2 hours on Day 1 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Onset of Action on Day 1</title>
          <description>Time to &gt;10% increase in FEV1 from pre-first dose, censored at 2 hours</description>
          <population>Full analysis set</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="1" upper_limit="86"/>
                    <measurement group_id="O2" value="6.0" lower_limit="4" upper_limit="117"/>
                    <measurement group_id="O3" value="11.0" lower_limit="7" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.501</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Volume on Day 1</title>
        <description>Change in residual volume during treatment</description>
        <time_frame>Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol on Day 1</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol on Day 1</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol on Day 1</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Volume on Day 1</title>
          <description>Change in residual volume during treatment</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.469" spread="0.5521"/>
                    <measurement group_id="O2" value="-0.408" spread="0.4803"/>
                    <measurement group_id="O3" value="-0.377" spread="0.4810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Volume on Day 3</title>
        <description>Change in residual volume during treatment</description>
        <time_frame>Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol on Day 3</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol on Day 3</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol on Day 3</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Volume on Day 3</title>
          <description>Change in residual volume during treatment</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.323" spread="0.4548"/>
                    <measurement group_id="O2" value="-0.313" spread="0.8946"/>
                    <measurement group_id="O3" value="-0.184" spread="0.6274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.648" spread="0.5173"/>
                    <measurement group_id="O2" value="-0.510" spread="0.6304"/>
                    <measurement group_id="O3" value="-0.510" spread="0.6257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.526" spread="0.5594"/>
                    <measurement group_id="O2" value="-0.481" spread="0.4994"/>
                    <measurement group_id="O3" value="-0.471" spread="0.6186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.353" spread="0.4561"/>
                    <measurement group_id="O2" value="-0.236" spread="0.7566"/>
                    <measurement group_id="O3" value="-0.094" spread="0.7118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Residual Capacity on Day 1</title>
        <description>Change in functional residual capacity during treatment</description>
        <time_frame>Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol on Day 1</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol on Day 1</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol on Day 1</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Residual Capacity on Day 1</title>
          <description>Change in functional residual capacity during treatment</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.344" spread="0.5097"/>
                    <measurement group_id="O2" value="-0.294" spread="0.4524"/>
                    <measurement group_id="O3" value="-0.277" spread="0.4279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Residual Capacity on Day 3</title>
        <description>Change in functional residual capacity during treatment</description>
        <time_frame>Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Oldaterol on Day 3</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Oldaterol on Day 3</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Oldaterol on Day 3</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Residual Capacity on Day 3</title>
          <description>Change in functional residual capacity during treatment</description>
          <population>Full analysis set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.490" spread="0.4654"/>
                    <measurement group_id="O2" value="-0.408" spread="0.6102"/>
                    <measurement group_id="O3" value="-0.382" spread="0.5610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.420" spread="0.5003"/>
                    <measurement group_id="O2" value="-0.405" spread="0.6111"/>
                    <measurement group_id="O3" value="-0.355" spread="0.6004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.255" spread="0.4003"/>
                    <measurement group_id="O2" value="-0.155" spread="0.7788"/>
                    <measurement group_id="O3" value="-0.075" spread="0.5881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose on Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.278" spread="0.4340"/>
                    <measurement group_id="O2" value="-0.206" spread="0.5925"/>
                    <measurement group_id="O3" value="-0.163" spread="0.5742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Airway Conductance on Day 1</title>
        <description>Change in specific airway conductance during treatment</description>
        <time_frame>Change from pre-dose to 1.25 hours on Day 1 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol on Day 1</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol on Day 1</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol on Day 1</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Airway Conductance on Day 1</title>
          <description>Change in specific airway conductance during treatment</description>
          <population>Full analysis set</population>
          <units>1/kPa*sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.1148"/>
                    <measurement group_id="O2" value="0.042" spread="0.0483"/>
                    <measurement group_id="O3" value="0.043" spread="0.1072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Airway Conductance on Day 3</title>
        <description>Change in specific airway conductance during treatment</description>
        <time_frame>Change from pre-dose on Day 1 to the following timepoints: pre-dose, 1.25, 8.25 and 12.25 hours on Day 3 (after the morning dose)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg RPL554 and Tiotropium/Olodaterol on Day 3</title>
            <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O2">
            <title>6 mg RPL554 and Tiotropium/Olodaterol on Day 3</title>
            <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Tiotropium/Olodaterol on Day 3</title>
            <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Airway Conductance on Day 3</title>
          <description>Change in specific airway conductance during treatment</description>
          <population>Full analysis set</population>
          <units>1/kPa*sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.608"/>
                    <measurement group_id="O2" value="0.046" spread="0.1060"/>
                    <measurement group_id="O3" value="0.016" spread="0.0890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.0824"/>
                    <measurement group_id="O2" value="0.050" spread="0.0682"/>
                    <measurement group_id="O3" value="0.049" spread="0.1193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" spread="0.1312"/>
                    <measurement group_id="O2" value="0.048" spread="0.0733"/>
                    <measurement group_id="O3" value="0.037" spread="0.1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" spread="0.0774"/>
                    <measurement group_id="O2" value="0.032" spread="0.0629"/>
                    <measurement group_id="O3" value="0.021" spread="0.1071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent until the end of the study, approximately 2 months for each patient</time_frame>
      <desc>As this is a cross over study, the number of patients at risk for each event was specified as the total number of patients who received the specified treatment in either Treatment Period 1, 2 or 3.</desc>
      <group_list>
        <group group_id="E1">
          <title>1.5 mg RPL554 and Tiotropium/Olodaterol</title>
          <description>1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
        </group>
        <group group_id="E2">
          <title>6 mg RPL554 and Tiotropium/Olodaterol</title>
          <description>6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
RPL554 Suspension: A PDE3/4 inhibitor
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
        </group>
        <group group_id="E3">
          <title>Placebo and Tiotropium/Olodaterol</title>
          <description>Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
Placebo: A placebo solution
Tiotropium/olodaterol (Respimat): An anticholinergic/Î²-agonist combination medication</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall not be permitted to present at symposia, national or regional professional meetings, and to publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the Clinical Trial subject to the publication policy described in the Protocol without prior written approval of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Maurer</name_or_title>
      <organization>Verona Pharma plc</organization>
      <phone>+19147675037 ext 9147675037</phone>
      <email>brian.maurer@veronapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

